Artisan Partners Limited Partnership Adds $306M in IQVIA Holdings Inc. ($IQV)
Key Points
- Artisan Partners Limited Partnership changed its IQVIA Holdings Inc. ($IQV) stake by 50.1% last quarter, boosting to 5,058,865 shares worth $915.96 million.
- Wall Street's consensus rating on $IQV is Strong Buy and an average price target of $226.95.
- $IQV last traded around $181.06.
Artisan Partners Limited Partnership increased its position in IQVIA Holdings Inc. ($IQV) by 50.1% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,058,865 shares of IQVIA Holdings Inc. after buying 1,687,480 shares during the quarter. Artisan Partners Limited Partnership's holdings in IQVIA Holdings Inc. were worth $915.96 million as of its most recent filing.
IQVIA Holdings Inc. ($IQV) Stock
IQVIA Holdings Inc. Earnings
Analysts Set New Price Targets
About IQVIA Holdings Inc.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.